Skip to main content
Optomed Oyj logo

Optomed Oyj — Investor Relations & Filings

Ticker · OPTOMED ISIN · FI4000410881 LEI · 7437009IVYWGEE4S7B77 HE Manufacturing
Open in API
Filings indexed 613 across all filing types
Latest filing 2024-06-26 Capital/Financing Update
Country FI Finland
Listing HE OPTOMED

About Optomed Oyj

https://www.optomed.com/

Optomed is a medical technology company that develops, commercializes, and manufactures handheld fundus cameras and related artificial intelligence (AI) solutions. The company specializes in portable retinal imaging devices designed for the early detection of blinding eye diseases, such as diabetic retinopathy, and other health conditions. Its technology combines portable hardware with AI-powered software to provide real-time analysis and results, enabling comprehensive eye screenings in various healthcare settings, from primary care clinics to emergency rooms. The solutions are designed to integrate into existing clinical workflows, improving access to eye care and transforming routine screenings into comprehensive health assessments.

Recent filings

Filing Released Lang Actions
Sisäpiiritieto: Optomed Oyj toteutti onnistuneesti suunnatun osakeannin keräten noin 7,9 miljoonaa euroa
Capital/Financing Update Classification · 100% confidence The document is a formal announcement by Optomed Oyj regarding the successful completion of a directed share issue (private placement) to raise approximately 7.9 million euros. It details the number of shares issued, the subscription price, the rationale for the capital raise, and the expected timeline for registration and trading. This falls under the category of capital structure changes and financing activities. It is not a report publication announcement (RPA) because it contains the primary details of the transaction itself rather than just announcing the availability of a separate report.
2024-06-26 Finnish
Sisäpiiritieto: Optomed Oyj toteutti onnistuneesti suunnatun osakeannin keräten noin 7,9 miljoonaa euroa
Share Issue/Capital Change Classification · 98% confidence The document is a formal announcement from Optomed Oyj, titled 'Sisäpiiritieto' (Insider Information), detailing the successful completion of a directed share issue ('suunnatun osakeannin') raising approximately 7.9 million euros. The text explicitly discusses the issuance of new shares, the subscription price, the exclusion of pre-emptive rights, and the expected registration date. This content directly relates to changes in the company's capital structure and fundraising activities. Therefore, the most appropriate classification is 'Capital/Financing Update' (CAP). It is not an Earnings Release (ER), Interim Report (IR), or a general Regulatory Filing (RNS), as it concerns a specific financing event.
2024-06-26 Finnish
Inside information: Optomed Plc successfully completes directed share issue raising approximately EUR 7.9 million
Capital/Financing Update Classification · 99% confidence The document is an 'Inside information' announcement from Optomed Plc regarding the successful completion of a 'directed share issue' which raised approximately EUR 7.9 million. This action involves issuing new shares to investors, deviating from pre-emptive subscription rights, and details the subscription price and expected registration dates. This clearly falls under the category of company fundraising, financing activities, or capital structure changes. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2024-06-26 English
Sisäpiiritieto, Optomed on allekirjoittanut osakassopimuksen yhteisyrityksen perustamisesta ZhongBaon kanssa
Regulatory Filings Classification · 95% confidence The document is a press release titled 'Sisäpiiritieto' (Inside Information) announcing that Optomed has signed a shareholder agreement to establish a joint venture in China with ZhongBao. It also includes a minor financial update regarding a credit loss provision. As this is a corporate announcement regarding business development and strategic partnerships, it falls under the category of general regulatory announcements (RNS) as it does not fit into specific categories like M&A (which usually implies full acquisition/merger) or specific financial reporting categories.
2024-06-24 Finnish
Sisäpiiritieto, Optomed on allekirjoittanut osakassopimuksen yhteisyrityksen perustamisesta ZhongBaon kanssa
Regulatory Filings Classification · 95% confidence The document is a formal announcement from Optomed Oyj, explicitly labeled as "Sisäpiiritieto" (Inside Information) and details a significant corporate action: signing a joint venture agreement in China with ZhongBao. It discusses strategic partnerships, ownership structure (19.9% vs 80.1%), market context (diabetes, aging population in China), and also includes an update on a specific credit loss provision related to a Chinese receivable. This type of material, announcing a major strategic transaction and related financial adjustments, is typically classified as a Regulatory Filing (RNS) if it's a general disclosure, or potentially related to M&A (TAR) or Capital (CAP). However, since it is a broad, material disclosure of non-financial results nature (not an ER, IR, or 10-K) and concerns a strategic partnership/investment, it fits best under the general 'Regulatory Filings' category (RNS) as a mandatory disclosure of inside information, or potentially 'M&A Activity' (TAR) due to the joint venture formation. Given the content is a direct disclosure of inside information regarding a strategic move, RNS is the most appropriate general regulatory fallback for material, non-standard announcements. The document length is short (3783 chars), but it is the primary disclosure itself, not an announcement *of* a report, so RPA is not applicable. Since it is a disclosure of inside information regarding a strategic partnership, RNS is the best fit among the provided options for a mandatory, material, non-periodic filing.
2024-06-24 Finnish
Inside Information: Optomed has signed a shareholder's agreement with Zhongbao Fund to establish a joint venture in China
Regulatory Filings Classification · 97% confidence The document is titled "Inside Information: Optomed has signed a shareholder's agreement with Zhongbao Fund to establish a joint venture in China." It details a significant corporate transaction (formation of a joint venture) and includes an update on credit risk accrual. This type of material announcement, which is material to the company's operations and structure but is not a standard periodic report (like 10-K or IR) or a specific event filing (like AGM or DIV), falls best under the category of general regulatory announcements or significant corporate actions that don't fit elsewhere. Since it is an immediate disclosure of a major business development, it is classified as a Regulatory Filing (RNS), which serves as the general category for significant, non-standard disclosures. It is not an Earnings Release (ER), Interim Report (IR), or a specific transaction like M&A (TAR), but rather a strategic partnership announcement.
2024-06-24 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.